TY  - GEN
AU  - Ahn,Chang Ho
AU  - Han,Kyung Ah
AU  - Yu,Jae Myung
AU  - Nam,Joo Young
AU  - Ahn,Kyu Jeung
AU  - Oh,Tae Keun
AU  - Lee,Hyoung Woo
AU  - Lee,Dae Ho
AU  - Kim,Jaetaek
AU  - Chung,Choon Hee
AU  - Park,Tae Sun
AU  - Kim,Byung Joon
AU  - Park,Seok Won
AU  - Park,Hyeong Kyu
AU  - Lee,Kwang Jae
AU  - Kim,Sang-Wook
AU  - Park,Jeong Hyun
AU  - Ko,Kwan Pyo
AU  - Kim,Chong Hwa
AU  - Lee,Hyunjin
AU  - Jang,Hak Chul
AU  - Park,Kyong Soo
TI  - Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)
SN  - 1463-1326
PY  - 2017///1010
KW  - Aged
KW  - Diabetes Mellitus, Type 2
KW  - blood
KW  - Dipeptidyl-Peptidase IV Inhibitors
KW  - adverse effects
KW  - Double-Blind Method
KW  - Drug Monitoring
KW  - Drug Resistance
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glycated Hemoglobin
KW  - analysis
KW  - Humans
KW  - Hyperglycemia
KW  - prevention & control
KW  - Hypoglycemia
KW  - chemically induced
KW  - Hypoglycemic Agents
KW  - Incidence
KW  - Male
KW  - Metformin
KW  - Middle Aged
KW  - Piperidones
KW  - Pyrimidines
KW  - Republic of Korea
KW  - epidemiology
KW  - Risk
KW  - Sulfonylurea Compounds
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/dom.12866
ER  -